Edited by Peter Hillerberg1 min readStories are generated from ORTEX data and reviewed by the ORTEX team. How we publish
Analysts made bold moves on consumer and healthcare names today. Abbott Laboratories drew the biggest upgrade of the session. TD Cowen's Joshua Jennings raised his target to $135 from $115 — a 17% jump — while reiterating a Buy rating. Abbott carries a $202 billion market cap. Short interest sits at just 1.4% of free float, signalling little bear pressure.
Lululemon got the opposite treatment. UBS analyst Jay Sole cut his target to $120 from $124 and kept a Hold rating. Short interest is already elevated at 9.7% of free float — one of the higher readings among large retailers. Bears appear well-positioned ahead of the cut.
Ulta Beauty bucked the consumer gloom. Deutsche Bank's Krisztina Katai raised her target to $695 from $692 and maintained a Buy. Short interest at Ulta stands at 5.4% of free float. Ample borrowing availability suggests shorts have plenty of room to add if the thesis sours.
Global Payments also saw a consensus target nudge higher to $103. KLA Corporation and Accenture both received upward target revisions from the broader analyst community.
The clearest theme today: healthcare attracts buyers while consumer discretionary faces growing skepticism.
ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data and reviewed by the ORTEX team. Content is informational only and does not constitute investment advice.
